Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With ROS1-Rearranged Advanced Lung Adenocarcinoma: A Multicenter, Retrospective Cohort Study
Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With ROS1-Rearranged Advanced Lung Adenocarcinoma: A Multicenter, Retrospective Cohort Study
复制标题
DOI：
10.1200/po.22.00614
复制
发表时间：
2023
影响因子：
4.6
通讯作者：
Yongchang Zhang
中科院分区：
文献类型：
--
作者：
Zhe Huang;Huan Yan;Liang Zeng;Qinqin Xu;Wenhuan Guo;Shaoding Lin;Wenjuan Jiang;Zhan Wang;Li Deng;Haoyue Qin;Xing Zhang;Fan Tong;Ruiguang Zhang;Zhaoyi Liu;Lin Zhang;Xiaorong Dong;Nong Yang;Yongchang Zhang
PURPOSE Immune checkpoint inhibitors (ICIs) exert robust antitumor activity in non–small-cell lung cancer (NSCLC) without actionable mutations. Apart from isolated case reports, the efficacy of PD-1 blockade in ROS1-rearranged NSCLC is currently unknown. METHODS This retrospective cohort study included 23 patients with ROS1-rearranged advanced lung adenocarcinoma who received ICI plus chemotherapy regardless of the treatment setting. ICI plus chemotherapy was received as a later-line regimen by 14 patients, as the first-line regimen by six patients, and after chemoradiotherapy by three patients. RESULTS All three patients who received chemoradiotherapy followed by ICI plus chemotherapy achieved partial response (PR) and had a progression-free survival (PFS) of .17.9 months. Of the six patients who received firstline ICI plus chemotherapy, five patients achieved PR and one had stable disease (SD), with a median PFS of 24.3 months (95% CI, 4.9 to 43.7). Of the 14 previously treated patients who received later-line ICI plus chemotherapy,theObjectiveResponseRate(ORR)was28.6%,theDiseaseControlRate(DCR)was92.9%,andthe medianPFSwas5.8months(95%CI,0.2to9.4).ThemediantimeonICItherapywas10.0months(95%CI,1.5 to32.5).Thedurationofresponsewas24.3months(95%CI,5.4to43.2)and4.8months(95%CI,2.3to12.7)for first-line (n = 5) and subsequent-line (n = 4) ICI plus chemotherapy, respectively. Of the 10 patients with brain metastasis before receiving ICI plus chemotherapy, four patients achieved intracranial PR and five patients achieved intracranial SD, achieving an intracranial ORR of 40.0% and an intracranial DCR of 90.0%. CONCLUSION Our retrospective study provides real-world clinical evidence that ROS1-rearranged NSCLCs benefit from ICI plus chemotherapy in any treatment setting, including patients who present with brain metastasis..
